Inhibrx Biosciences (INBX) Free Cash Flow (2023 - 2025)

Inhibrx Biosciences (INBX) has reported Free Cash Flow for 3 consecutive years, with -$30.1 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Free Cash Flow rose 29.57% year-over-year to -$30.1 million; the TTM figure through Dec 2025 stood at -$129.8 million (up 34.1% YoY), while the FY2025 annual figure was -$129.8 million, up 34.1% from the prior year.
• Free Cash Flow rose to -$30.1 million in Q4 2025 per INBX's latest filing, from -$33.9 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$29.9 million in Q2 2025 and bottomed at -$63.4 million in Q1 2024.
• Historically, Free Cash Flow has averaged -$44.2 million across 3 years, with a median of -$39.3 million in 2024.
• On a YoY basis, Free Cash Flow climbed as much as 47.72% in 2025 and fell as far as 0.69% in 2025.
• Inhibrx Biosciences' Free Cash Flow stood at -$60.3 million in 2023, then climbed by 29.03% to -$42.8 million in 2024, then advanced by 29.57% to -$30.1 million in 2025.
• Business Quant data shows INBX's Free Cash Flow at -$30.1 million in Q4 2025, -$33.9 million in Q3 2025, and -$29.9 million in Q2 2025.